<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <contributors>
    <authors>
      <author>Caronna, E.</author>
      <author>José Gallardo, V.</author>
      <author>Alpuente, A.</author>
      <author>Torres-Ferrus, M.</author>
      <author>Sánchez-Mateo, N.M.</author>
      <author>Viguera-Romero, J.</author>
      <author>López-Veloso, A.C.</author>
      <author>López-Bravo, A.</author>
      <author>Gago-Veiga, A.B.</author>
      <author>Irimia Sieira, P.</author>
      <author>Porta-Etessam, J.</author>
      <author>Santos-Lasaosa, S.</author>
      <author>Pozo-Rosich, P.</author>
      <author>Spanish, CGRP-COVID, Study, Group</author>
    </authors>
  </contributors>
  <titles>
    <title>Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications [Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras]</title>
    <secondary-title>Neurología (Barc.)</secondary-title>
  </titles>
  <doi>10.1016/j.nrl.2021.03.003</doi>
  <pages/>
  <volume/>
  <number/>
  <dates>
    <year>2021</year>
    <pub-dates>
      <date>2021</date>
    </pub-dates>
  </dates>
  <abstract/>
</record>

</records>
</xml>